312 reports of this reaction
2.8% of all PALONOSETRON HYDROCHLORIDE reports
#7 most reported adverse reaction
NEUTROPENIA is the #7 most commonly reported adverse reaction for PALONOSETRON HYDROCHLORIDE, manufactured by Apotex Corp.. There are 312 FDA adverse event reports linking PALONOSETRON HYDROCHLORIDE to NEUTROPENIA. This represents approximately 2.8% of all 11,239 adverse event reports for this drug.
Patients taking PALONOSETRON HYDROCHLORIDE who experience neutropenia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
NEUTROPENIA is a less commonly reported adverse event for PALONOSETRON HYDROCHLORIDE, but still significant enough to appear in the safety profile.
In addition to neutropenia, the following adverse reactions have been reported for PALONOSETRON HYDROCHLORIDE:
The following drugs have also been linked to neutropenia in FDA adverse event reports:
NEUTROPENIA has been reported as an adverse event in 312 FDA reports for PALONOSETRON HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
NEUTROPENIA accounts for approximately 2.8% of all adverse event reports for PALONOSETRON HYDROCHLORIDE, making it a notable side effect.
If you experience neutropenia while taking PALONOSETRON HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.